In a move that signals a deepening biotechnological alliance between Moscow and Beijing, Chinese health regulators have reportedly begun an accelerated review of Russia’s first sovereign mRNA cancer vaccine, Enteromix (also known in clinical circles as Neooncovac). According to reports from the Daily CPEC and regional biotech monitors on March 30, 2026, the goal is to grant the therapy regulatory approval for use within China before the end of the year.
The Technology: Personalized Immunotherapy
Developed by the Gamaleya National Research Center—the institution behind the Sputnik V COVID-19 vaccine—this new therapeutic platform marks Russia’s successful pivot to messenger RNA (mRNA) technology.
- Mechanism: Unlike preventive vaccines, this is a therapeutic “cancer vaccine.” It uses a patient’s own tumor genetic data to “train” the immune system to recognize and destroy specific malignant cells.
- Pre-Clinical Success: Russian scientists report that in animal trials, the vaccine achieved 60% to 80% tumor reduction and significantly suppressed metastasis.
- AI-Driven Synthesis: The manufacturing process reportedly utilizes artificial neural networks to streamline the creation of personalized doses, potentially reducing production time from weeks to just a few days.
Strategic Cooperation: The Shanghai-Moscow Connection
The Chinese review follows a series of high-level working visits in early 2026 between experts from Sechenov First Moscow State Medical University and major university hospitals in Shanghai.
- Clinical Integration: The two nations have agreed to strengthen cooperation on personalized cancer treatments, specifically focusing on China’s experience in scaling cell-based therapies and genome editing.
- Shared Quality Control: Talks in Shanghai focused on a state-run quality control system that would allow the Russian mRNA vaccine to be produced and distributed safely within the Chinese medical infrastructure.
- BRICS Bio-Diplomacy: Analysts view this collaboration as a cornerstone of “BRICS bio-diplomacy,” creating a high-tech medical ecosystem that is entirely decoupled from Western pharmaceutical giants like Pfizer-BioNTech or Moderna.
Roadmap to Approval
The vaccine is currently moving through several critical milestones in both countries:
- Russia: The Ministry of Health recently announced plans to include the mRNA vaccine in the country’s compulsory medical insurance program starting in 2026, making it free for Russian citizens.
- China: The National Medical Products Administration (NMPA) is evaluating Phase I/II clinical data. If approved, it would become the first Russian-developed mRNA therapy to enter the Chinese market.
- Indications: While initially tested on melanoma, research is rapidly expanding to target colorectal cancer, glioblastoma (brain cancer), and non-small cell lung cancer.
| Milestone | Expected Date | Status |
| China Regulatory Approval | Q4 2026 | Under Review (Fast-Track). |
| Russia Insurance Inclusion | Jan 2026 | Draft Resolution Approved. |
| Melanoma Clinical Rollout | Mid-2026 | Pilot Batches Verified. |
| Lung Cancer Phase I | Q3 2026 | Planned. |
Global Implications
The potential approval of Enteromix in China represents a challenge to the global pharmaceutical status quo. By providing a cost-effective, personalized alternative to expensive Western drug therapies, the China-Russia partnership could redefine oncology for “aligned” nations across the Global South.
However, some international health experts urge caution, noting that while the 90% efficacy claims in animal trials are impressive, large-scale Phase III multicenter studies have not yet been published in high-impact, peer-reviewed international journals.
